Therapeutic efficacy of ethanolic extract of *Aerva javanica* aerial parts in the amelioration of CCl₄-induced hepatotoxicity and oxidative damage in rats

Ahmed H. Arbab¹, Mohammad K. Parvez¹*, Mohammed S. Al-Dosari¹, Adnan J. Al-Rehaily¹, Khalid E. Ibrahim², Perwez Alam¹, Mansour S. Alsaid¹,³ and Syed Rafatullah³

¹Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; ²Department of Pathology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia; ³Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

**Abstract**

**Background:** Liver diseases, the fifth most common cause of global death, can be metabolic, toxin-induced, or infective. Though approximately 35 Saudi medicinal plants are traditionally used to treat liver disorders, the hepatoprotective potential of *Aerva javanica* has not been explored.

**Objective:** To investigate the antioxidative and hepatoprotective effect of *Aerva javanica*.

**Design:** Total ethanol extract of *A. javanica* aerial parts was prepared and tested on DCFH-toxicated HepG2 cells ex vivo, and in CCl₄-injured Wistar rats in vivo. MTT assay was used to determine cell viability and the serum biochemical markers of liver injury as well as histopathology was performed. In vitro 1,1-diphenyl-2-picrylhydrazyl and β-carotene free-radical scavenging assay and phytochemical screening of the extract were done. Furthermore, *A. javanica* total extract was standardized and validated by high-performance thin layer chromatographic method.

**Results:** MTT assay showed that, while DCFH-injured cells were recovered to ~56.7% by 100 µg/ml of the extract, a 200 µg/ml dose resulted in hepatocytes recovery by ~90.2%. Oral administration of the extract (100 and 200 mg/kg bw/day) significantly normalized the serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, gamma-glutamyl transferase, alkaline phosphatase, bilirubin, cholesterol, high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein, triglyceride, and malondialdehyde levels, including tissue nonprotein sulphydryl and total protein in CCl₄-injured rats. In addition, the histopathology of dissected liver also revealed that *A. javanica* cured the tissue lesion compared to silymarin treatment. In vitro assays revealed strong free-radical scavenging ability of the extract and presence of alkaloids, flavonoids, tannins, sterols, and saponins where rutin, a well-known antioxidant flavonoid, was identified.

**Conclusions:** Our findings demonstrate the potential of *A. javanica* in the attenuation of ex vivo and in vivo hepatotoxicity and oxidative damage. This further suggests its therapeutic value in various liver diseases. However, isolations of the active principles, their mechanisms of action, and other therapeutic contributions remain to be addressed.

**Keywords:** *Aerva javanica*; hepatoprotection; oxidative stress; DCFH; CCl₄; rutin; liver diseases

Received: 30 December 2015; Revised: 1 March 2016; Accepted: 4 March 2016; Published: 7 April 2016

Liver is one of the most vital organs of the body, considered to be the metabolic ‘engine room’. Major functions of the liver include carbohydrate, protein, and fat metabolism as well as secretion of bile, and the storage and detoxification of several drugs and xenobiotics. Liver diseases can be classified as acute or chronic hepatitis (inflammatory liver diseases), hepatitis (non-inflammatory liver diseases), and cirrhosis. Liver disorders can be attributed to toxins like aflatoxin, chlorinated hydrocarbons, and certain drugs. Other factors include infectious pathogens such as hepatitis viruses (1) and alcohol consumption (2). Drug-induced liver toxicity accounts for approximately one-half of the cases of acute liver failure (3). Currently, there is a real need for effective therapeutic agents, especially natural products with a minimal incidence of toxic effects. Despite the
significant popularity of several mono- and poly-herbal preparations for liver diseases (4), only few (e.g., silymarin) have been approved for protection or treatment of liver disorders (5). Nevertheless, in recent years, many phyto-products have been investigated against hepatotoxin-induced liver damage (6–10).

The genus Aerva belongs to the plant family Amaranthaceae, and there are approximately 28 species in this genus (11). Aerva javanica is an erect, much-branched perennial herb that is a native of Africa and also distributed in various parts of the world. Different parts of the plant have wide applications in folk medicine, for example the whole plant is used for chest pain, diarrhea, and as a diuretic and demulcent. A decoction prepared from the aerial parts of A. javanica is used as a gargle to cure gum swelling and toothache. Though the seeds are used for headache relief, paste from the flowers and leaves is used externally to heal the wounds and the inflammation of joints (12). Also, it is used for dysentery, gonorrhea, and hyperglycemia (13). Previous biological screenings revealed the numerous biological activities of A. javanica. Its ethanolic and aqueous extracts showed significant anti-diarrheal activity at a dose level of 800 mg/kg in Wistar rats (14). In addition, A. javanica exhibited antibacterial, anti-fungal (15–17), smooth muscle relaxant, and anti-ulcer activities (13). The alcoholic extract of root of A. javanica was shown to possess significant nephro-protective activity against cisplatin- and gentamycin-induced renal toxicity in experimental animals (18).

A phytochemical analysis of A. javanica has revealed the presence of polyphenols, terpenoids, flavonoids, and alkaloids (11). Notably, four new ecdysteroids, aervecdy-steroid A–D (1–4), and three new acetylated flavone glycosides have been isolated from the flowers (19). In addition, heptacosane (3-allyl-6-methoxyphenol) and pentacosane were identified as the major components of the A. javanica seed oil (20). With this background information, the present study was intended to investigate the antioxidant and hepatoprotective activities of ethanolic extract of the aerial parts of A. javanica.

Materials and methods

Plant materials

Aerial parts (leaves, stems, and inflorescences) of A. javanica (Family: Amaranthaceae) were collected from Taif, Kingdom of Saudi Arabia. The plant was authenticated by an expert plant taxonomist at the herbarium of College of Pharmacy, King Saud University, Riyadh, and a voucher specimen (No. 16281) was deposited.

Preparation of A. javanica total ethanolic extract

The shade-dried powdered plant material (400 g) were soaked in 70% aqueous ethanol (Merck, Germany) for 2 days at room temperature and filtered. The extraction process was repeated twice with the same solvent. Then, the extracts were evaporated using a rotary evaporator (Buchi, Switzerland) under reduced pressure at 40°C. The obtained semi-solid extracts (37.68 g) were stored at −20°C until used for further study.

Human hepatoma cell culture and drugs

Human hepatoma cell line (HepG2) was grown in RPMI-1640 medium, supplemented with 10% heat-inactivated bovine serum (Gibco, USA), 1 × penicillin–streptomycin, and 1 × sodium pyruvate streptomycin (HyClone Laboratories, USA) at 37°C in a humified chamber with 5% CO2 supply. 2,7-Dichlorofluorescein (DCFH; Sigma, USA) was used to induce cytotoxicity in cultured HepG2 cells. Silymarin (Sigma, USA) was used as standard hepatoprotective drug in rats.

Ex vivo hepatoprotective assay of A. javanica total ethanolic extract

HepG2 cells were seeded (0.5 × 10⁵ cells/well, in triplicate) in a 96-well flat-bottom plate (Becton-Dickinson Labware, USA) and grown over night. The cytotoxicity of DCFH was determined by using MTT assay (MTT-Cell proliferation Assay Kit, Tervigen). The concentration of DCFH that caused a 50% inhibition of HepG2 cell proliferation (IC50: 100 μg/ml) was used as a cytotoxic dose. A. javanica total extract was dissolved in DMSO (100 mg/ml), followed by dilution with RPMI-1640 media to four doses (25, 50, 100, and 200 μg/ml). The final concentration of DMSO used never exceeded >0.1% and was therefore tolerated by cultured cells. The culture monolayer was replenished with RPMI-1640 containing 100 μg/ml DCFH plus a dose of A. javanica, including untreated as well as DCFH-treated controls. The treated cells were incubated for 48 h at 37°C. Cells were treated with MTT reagent (10 μl/well) and further incubated for 3–4 h. Upon the appearance of a purple color, detergent solution (100 μl) was added to each well and further incubated for 1.5 h. The optical density (OD) was recorded at 570 nm in a microplate reader (BioTek, ELX800). Nonlinear regression analysis was performed in Excel software to determine the cell survival (%) using the following equation:

\[
\text{Cell Survival(\%)} = \frac{OD(s) - OD(b)}{OD(c) - OD(b)} \times 100
\]

where OD(s), OD(b), and OD(c) are the absorbance of sample, blank, and negative control, respectively.

Microscopy

The morphological investigation of the cultured hepatoma cells was done under an inverted microscope (Optica, 40 ×, and 100 ×) to observe any changes in the cells cultured with different concentrations of A. javanica total extract and/or DCFH at 24 and 48 h.
**In vivo hepatoprotective activity of A. javanica total extract: Experimental design and treatment**

Thirty healthy male Wistar rats were obtained from the Experimental Animal Care Center (EACC) of the College of Pharmacy, King Saud University, Riyadh. Animals were kept in polycarbonate cages in a room free from any source of contamination, artificially illuminated (12 h dark/light cycle) at controlled temperature (25 ± 2°C). After acclimatization, animals were randomized and divided into five groups (I–V) of six animals each. Group I served as untreated control and fed orally with normal saline 1 ml. Group II received CCl₄ in liquid paraffin (1:1) 1.25 ml/kg bw intraperitoneally (i.p.) and served as negative control. Similarly, group (III, IV and V) also received CCl₄. While groups III and IV were treated with the standard drug silymarin (21) at a dose of 100 mg/kg.bw and 200 mg/kgbw, respectively, group V was treated with the standard drug silymarin (21–23) at a dose of 10 mg/kgbw for 3 weeks. Blood was collected for serum biochemistry and animals were sacrificed for liver dissection. All animals received human care in compliance with the guidelines of the Ethics Committee of the Experimental Animal Care Society, College of Pharmacy, King Saud University, Riyadh.

**Estimation of marker enzymes and bilirubin**

Serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) (24), alkaline phosphatase (ALP) (25), gamma-glutamyl transferase (GGT) (26), and bilirubin (27) were determined using Reflotron Plus Analyzer and Roche kits (Roche Diagnostics GmbH, Mannheim, Germany).

**Estimation of lipid profile**

Total cholesterol (28), triglycerides (29) and high-density lipoproteins (HDL) (30) levels were estimated in serum using Roche diagnostic kits (Roche Diagnostics GmbH, Mannheim, Germany).

**Determination of malondialdehyde (MDA)**

The method reported by Utley et al. (31) was followed. In brief, the liver tissues were removed and homogenized in 0.15 M KCl (at 4°C; Potter-Elvehjem type C homogenizer) to give a 10% w/v homogenate. The absorbance of the solution was then read at 532 nm. The content of MDA (nmol/g wet tissue) was then calculated, by reference to a standard curve of MDA solution.

**Estimation of nonprotein sulfhydryl (NP-SH)**

Hepatic NP-SH was measured according to the method of Sedlak and Lindsay (32). The liver tissues were homogenized in ice-cold 0.02 mM ethylene diamine tetraacetic acid (EDTA). The absorbance was measured within 5 min of addition of 5,5′ dithio-bis(2-nitrobenzoic acid) (DTNB) at 412 nm against a reagent blank.

**Determination of total protein (TP)**

Serum TP was estimated by the kit method (Crescent Diagnostics, Jeddah, Saudi Arabia). The absorbance (Abs) of the samples were recorded at 546 nm and concentration of serum TP was calculated using the following equation:

\[
\text{Serum TP} = \left( \frac{\text{Abs of sample}}{\text{Abs of standard}} \right) \times \text{Concentration of standard}
\]

**Histopathological evaluation**

The animals were sacrificed under ethyl ether anesthesia and livers were quickly removed. Liver tissues were fixed in 10% neutral buffered formalin for 24 h and processed overnight for dehydration, clearing, and paraffin impregnation using an automatic tissue processor (Sakura, Japan). The specimens were embedded in paraffin blocks using embedding station (Sakura, Japan) and sections of 4 micron thickness were cut using rotary microtome (Leica-RM2245, Germany) and stained with hematoxylin and eosin (H&E) stains using routine procedures (33). The stained sections were observed under light microscopy, and the required images were taken with digital microscopic mounted camera (OMX1200C, Nikon, Japan).

**Antioxidant assay of A. javanica total extract**

1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay

Antioxidant activity was estimated by free-radical scavenging ability of the total extract against DPPH according to the method described elsewhere (34), but with minor modifications to suite 96-well microplate format. DPPH is a molecule containing a stable free radical, and in the presence of an antioxidant agents, which can donate an electron to the DPPH, the purple color typical for free DPPH radical decays, and the change in absorbance (\(\lambda = 517\) nm) is measured spectrophotometrically. In brief, 100 μl of different concentrations (31.25, 62.5, 125, 250, and 500 μg/ml) of the extract was mixed with 40 μl of DPPH (0.2 mM in methanol) in wells of a 96-well microplate. Appropriate control was prepared using the solvent only in addition to the same amount of DPPH reagent to get rid of any inherent solvent effect. Ascorbic acid was used as standard. After 30 min incubation at 25°C, the decrease in absorbance was measured using microplate reader. The test was carried out in triplicate. The radical-scavenging activity was calculated from the equation:

\[
\% \text{ of radical scavenging activity} = \left[ 1 - \frac{\text{Abs}_{\text{sample}}}{\text{Abs}_{\text{control}}} \right] \times 100
\]

**β-Carotene-linoleic acid bleaching assay**

The antioxidant activity of A. javanica total extract was evaluated using the β-carotene bleaching method (35) with...
minor modifications for working with 96 well plate. Briefly, 0.25 mg β-carotene was dissolved in 0.5 ml of chloroform and added to flasks containing 12.5 μg of linoleic acid and 100 mg of Tween-40. The chloroform was evaporated at 43°C using speed vacuum concentrator (Savant, Thermo Electron Co.). The resultant mixture was immediately diluted to 25 ml with distilled water and shaken vigorously for 2–3 min to form an emulsion. A 200 μl aliquot of the emulsion was added to wells of a 96-well plate containing 50 μl of the extract or gallic acid (500 μg/ml). A control containing solvent instead of extract was also prepared. The plate was incubated at 50°C for 2 h. Absorbance was read at 470 nm at 30 min intervals using microplate spectrophotometer (BioRad). The test was carried out in triplicate. The antioxidant activity was estimated using two different methods where the kinetic curve was initially obtained by plotting absorbance of each sample against time. Then, antioxidant activity was expressed as % inhibition of lipid peroxidation using the formula:

\[ \% \text{Inhibition} = \frac{([A_s(120) - A_c(120)])}{(A_c(0))} \times 100 \]

where \(A_s(120)\) and \(A_c(120)\) are the absorbance of the sample and control, respectively, at time 120 min, and \(A_c(0)\) is the absorbance of the control at time 0 min.

**In vitro phytochemical screening of ethanolic extract of A. javanica**
Qualitative phytochemical screening tests for major secondary metabolites, which included alkaloids, flavonoids, anthraquinones, tannins, saponins, and cardiac glycosides, were performed using standard procedures (36–38).

**Standardization of ethanolic extract of A. javanica by HPTLC method**
A high-performance thin layer chromatography (HPTLC) method was used to standardize the 70% ethanol extract of \(A.\ javanica\) as described elsewhere (39). The chromatography was carried out on 10 × 10 cm precoated silica gel F254 RP-HPTLC plate, using rutin as the reference standard. Several mobile phases were tried to get good resolution and separation of different compounds present in the \(A.\ javanica\) ethanol extract. Based on our observations, we selected acetonitrile and water in the ratio of 4:6 as suitable mobile phase to carry out the standardization of the extract. The standard along with samples was applied on the HPTLC plate by CAMAG Automatic TLC Sampler-4. The plate was developed under controlled condition in CAMAG Automated Developing Chamber-2 and scanned by CAMAG TLC Scanner-3 (λ = 360 nm).

**Statistical analysis**
Results were expressed as mean ± SEM. Total variation present in a set of data was estimated by one-way analysis of variance (ANOVA) followed by Dunnet’s test. \(P <0.01\) was considered significant.

**Results**

**Effect of \(A.\ javanica\) on cell morphology**
Microscopic observations showed considerable cytotoxic effect of DCFH on the HepG2 cells as reflected by altered morphology compared to untreated cells. Interestingly, the DCFH-treated cells supplemented with 100 and 200 μg/ml of \(A.\ javanica\) extract were morphologically different from those treated with DCFH alone but comparable to untreated cells (data not shown).

**Hepatoprotective and cell proliferative effect of \(A.\ javanica\)**
MTT test showed hepatoprotective effect of \(A.\ javanica\) ethanol extract in a dose-dependent manner against DCFH-toxicity. While DCFH-toxicized cells were recovered to about 56.7% after supplementation with 100 μg/ml of \(A.\ javanica\) extract, further doubling the dose (200 μg/ml) resulted in hepatocytes recovery by about 90.2% (Fig. 1).

**In vivo effect of \(A.\ javanica\) extract on biochemical markers**
Based on the ex vivo hepatoprotective activity on HepG2 cells, the effects of \(A.\ javanica\) extract were further examined in the experimental animal model. The administration of CCl₄ dramatically elevated the serum SGOT, SGPT, GGT, ALP, and bilirubin levels compared to the normal control group (\(P <0.0001\)), indicating significant hepatotoxicity of CCl₄ treatment (Table 1). In contrast, oral administration of \(A.\ javanica\) extract significantly normalized the biochemical parameters in CCl₄-treated rats, compared to the CCl₄-treated group (Table 1). Moreover, CCl₄-induced toxicity caused significant elevation in lipid profile including cholesterol, triglycerides, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) and a reduction in the HDL levels in serum. The 3-week pretreatment of rats with two doses (250 and 500 mg/kg.bw/day) of \(A.\ javanica\) extract

**Fig. 1.** MTT-cell proliferation assay showing hepatoprotective effect of \(A.\ javanica\) total ethanolic extract against DCFH-induced hepatotoxicity in cultured HepG2 cells.
### Table 1. Effect of A. javanica total ethanolic extract on CCl4-induced hepatotoxicity-related parameters in rats

| Treatment group | SGOT (U/l) | SGPT (U/l) | ALP (U/l) | GGT (U/l) | Bilirubin (mg/dl) |
|-----------------|------------|------------|-----------|-----------|------------------|
| Control         | 107.45 ± 5.31 | 28.83 ± 2.20 | 321.66 ± 13.88 | 4.06 ± 0.32 | 0.54 ± 0.01     |
| CCl4            | 294.83 ± 8.37** | 230.83 ± 9.6** | 515.16 ± 13.7** | 12.85 ± 0.98** | 2.16 ± 0.08**   |
| A. javanica (100 mg) + CCl4 | 279.33 ± 7.41** | 174.33 ± 6.3** | 437.00 ± 8.6** | 10.28 ± 0.43** | 1.81 ± 0.05**   |
| A. javanica (200 mg) + CCl4 | 246.00 ± 3.7** | 140.16 ± 4.04** | 412.66 ± 8.8** | 6.86 ± 0.33** | 1.54 ± 0.02**   |
| Silymarin (10 mg) + CCl4 | 136.66 ± 6.00** | 85.66 ± 4.31** | 396.33 ± 7.62** | 5.58 ± 0.28** | 1.06 ± 0.06**   |

All values represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA, followed by Dunnet’s multiple comparison test. *As compared with normal group. **As compared with CCl4-only group.

significantly reduced the cholesterol, triglycerides, LDL, and VLDL levels and improved the HDL level in a dose-dependent manner (Table 2). Silymarin, on the other hand, significantly prevented the CCl4-induced elevation in marker enzymes and lipid profile. Furthermore, our results indicated that treatment with A. javanica also resulted in a significant increase in MDA and decrease in marker enzymes and lipid profile. Further-

### Histological improvement by A. javanica total extract

The histological examination of rat liver tissues revealed evidence of hepatic necrosis and fatty degenerative changes in CCl4-injured animals (Fig. 2a and b). Compared to this, the A. javanica-treated (100 mg/kg.bw/day) animals exhibited congested central vein with mild necrosis and fatty changes (Fig. 2c). On the other hand, the higher dose (200 mg/kg.bw/day) of A. javanica showed normal hepatocytes and central vein with full recovery that was comparable to silymarin administration (Fig. 2d and e). This finally confirmed the hepatoprotective efficacy of A. javanica total extract.

### In vitro antioxidant activity of A. javanica

The total extract of A. javanica was able to reduce the stable free-radical DPPH to the yellow-colored DPPH (Fig. 3). At 500 μg/ml dose, the observed antioxidant activities were comparable to that of the positive control (ascorbic acid). In accordance with the DPPH radical scavenging assay results, A. javanica showed high antioxidant activity in β-carotene–linoleic acid bleaching assay (Fig. 4).

### Phytochemical screening of the total extract

The qualitative phytochemical screening of the A. javanica total extract showed the presence of alkaloids, flavonoids, tannins, sterols, and saponins and the absence of anthraquinones and cardiac glycosides.

### Identification of rutin, a biflavonoid in A. javanica extract

The HPTLC analysis revealed the presence of rutin, a well-known antioxidant flavonoid in the total extract (Fig. 5a). Using acetonitrile and water as suitable mobile phase, the compact spot of rutin was found at Rf = 0.65 (Fig. 5b). Also, a good separation of different phytoconstituents present in the ethanol extract using the same mobile phase was achieved (Fig. 5c). The dried extract of A. javanica was found to contain 2.53 μg/mg of rutin.

### Discussion

Among more than 100 species of medicinal plants documented in Saudi Arabia, approximately 35 plants are used in Saudi folk medicine for the treatment of liver disorders. However, most of them remain popular without scientific rationale. Of these, the hepatoprotective potential of Aerva javanica has been neither explored in traditional practices nor with experimental approaches.

### Table 2. Effects of A. javanica total ethanolic extract on CCl4-induced lipid profile changes in rats

| Treatment group | TC (mg/dl) | TG (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) |
|-----------------|------------|------------|-------------|-------------|--------------|
| Control         | 109.83 ± 3.94 | 59.01 ± 2.74 | 55.18 ± 2.40 | 42.84 ± 3.22 | 11.80 ± 0.54 |
| CCl4            | 206.00 ± 4.3** | 151.16 ± 4.61** | 26.25 ± 1.79** | 149.51 ± 4.28** | 30.23 ± 0.92** |
| A. javanica (100 mg) + CCl4 | 163.33 ± 5.28** | 105.85 ± 5.20** | 29.76 ± 1.02** | 112.39 ± 6.82** | 21.17 ± 1.04** |
| A. javanica (200 mg) + CCl4 | 143.66 ± 5.47** | 82.61 ± 3.65** | 35.41 ± 2.26** | 91.72 ± 2.52** | 16.52 ± 0.70** |
| Silymarin (10 mg) + CCl4 | 147.66 ± 4.88** | 110.16 ± 5.26** | 40.41 ± 2.97** | 85.21 ± 5.98** | 22.02 ± 1.05** |

All values represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA, followed by Dunnet’s multiple comparison test. *As compared with normal group. **As compared with CCl4-only group.
In this study, we have, therefore, evaluated the hepatoprotective and antioxidative potential of *A. javanica* total ethanolic extract against DCFH-induced cytotoxicity in HepG2 cells and CCl₄-induced liver damage in rats, respectively. DCFH is generally used for the quantitative assessment of oxidative stress generated by free radicals.

| Treatment group                          | MDA (nmol/g)     | NP-SH (nmol/g) | TP (g/l)     |
|-----------------------------------------|------------------|---------------|-------------|
| Control                                 | 0.50 ± 0.02      | 7.39 ± 0.53   | 113.76 ± 2.81 |
| CCl₄                                    | 4.82 ± 0.29***a  | 3.86 ± 0.44***a | 49.11 ± 1.82***a |
| *A. javanica* (100 mg) + CCl₄           | 2.77 ± 0.10***ab | 5.67 ± 0.47***ab | 67.86 ± 2.94***ab |
| *A. javanica* (200 mg) + CCl₄           | 1.79 ± 0.14***ab | 6.16 ± 0.40***ab | 82.23 ± 4.44***ab |
| Silymarin (10 mg) + CCl₄                | 1.37 ± 0.16***ab | 6.52 ± 0.31***ab | 91.81 ± 4.08***ab |

All values represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA, followed by Dunnet's multiple comparison test. *As compared with normal group. **As compared with CCl₄-only group.

*Fig. 2.* The histopathology of experimental rat liver at 100 ×, 200 ×, and 400 × magnifications. Histograms showing the following: (a) healthy tissues with normal hepatocytes and central vein; (b) CCl₄-injured tissue with necrosis and fatty degenerative changes; (c) tissue with congested central vein with necrosis and fatty changes after *A. javanica* (100 mg) + CCl₄ treatment; (d) liver with normal hepatocytes and central vein with full recovery after *A. javanica* (200 mg) + CCl₄ treatment; and (e) liver with normal hepatocytes and fully recovered central vein after silymarin (10 mg) + CCl₄ treatment.
through the principle of oxidation of DCFH to the fluorescent DCF (40). However, we used this agent because of its toxic effect on cultured cell, ex vivo. A. javanica total extract promoted HepG2 cell proliferation and recovery in a dose-dependent manner. These findings were further supported by microscopic examination of cell morphology and growth.

To further confirm the ex vivo cell proliferative effects, the in vivo hepatoprotective potential activity of A. javanica total extract was examined in CCl4-injured rats. CCl4 is a common hepatotoxic used in the experimental study of liver diseases that induces free-radical generation in liver tissues. In vivo, it is transformed to active free radicals that bind to macromolecules resulting in lipid peroxidation that causes cell injury (41, 42). Clinical symptoms of CCl4-induced acute liver injury include jaundice and elevated levels of serum SGOT, SGPT, and ALP, indicators of liver necrosis and inflammation (43). In the present study, pretreatment with two doses of A. javanica total extract (100 and 200 mg/kg.bw) showed its ability to reduce the SGOT, SGPT, GGT, ALP, and bilirubin levels significantly in a dose-dependent manner. In addition, A. javanica extract was able to normalize the serum cholesterol and triglycerides and HDL levels in CCl4-injured rats. The hepatoprotective effect of A. javanica at 200 mg/kg.bw was comparable to standard drugs silymarin (10 mg/kg.bw). The rise of serum enzyme SGOT and SGPT levels had indicated that hepatocyte cells were injured where the leakage of cell membrane had contributed to the accumulation of these enzymes into the plasma (44). The significant reduction in the levels of LDL, and total cholesterol in the A. javanica-treated rats and an increase in the HDL level further indicated the hepatoprotective potential of A. javanica.

MDA is produced during the peroxidation of polyunsaturated fatty acids, and the amount of MDA is a marker for cell membrane lipid peroxidation and cell damage (45). Treatment with A. javanica extract or silymarin reduced the level of MDA in livers with CCl4-induced damage, which suggests that the tested extract was protective and curative against liver toxicity.

NP-SH plays an important role in the defense against oxidative cellular damage (46). In our study, the liver NP-SH level in the CCl4-treated group was markedly reduced when compared with the control group. Pretreatment of rats with A. javanica total extract or silymarin replenished NP-SH concentration as compared with CCl4 only treated animals, suggesting free-radical scavenging activity of the tested extract.
The level of TP would be decreased in hepatotoxic conditions due to defective protein biosynthesis in liver. Thus, the reduction in TP level is a further indication of liver damage in CCl4-injured animals (47). In our study, the level of TP has been restored to the normal value, indicating the curative action of *A. javanica* total ethanolic extract. Moreover, most of the parameters in the animal group that received CCl4 plus *A. javanica* extract had values comparable to those of the group receiving CCl4 plus silymarin. This very clearly indicated that *A. javanica* was efficient to attenuate CCl4-induced hepatotoxicity in rats.

Conducting different assay methods for the evaluation of antioxidant activity (48, 49) is now commonly recommended. In our *in vitro* assays, the antioxidant activity of *A. javanica* ethanolic extract revealed strong antioxidant activities in both DPPH and β-carotene methods. In addition, our preliminary phytochemical screening of the *A. javanica* total extract showed the presence of alkaloids, flavonoids, tannins, sterols, and saponins. Taken together, the antioxidant activity of the *A. javanica* extract could be attributed to the presence of antioxidant and free-radical scavenging phytoconstituents, such as polyphenol, flavonoids, and saponins, which are known to have hepatoprotective activities. Rutin (3,3′,4′,5,7-pentahydroxyflavone-3-rhamnoglucoside), a biflavonoid found in many plants, has a wide range of pharmacological properties against various metabolic and infectious diseases (50). The reactive-species-mediated *in vivo* hepatotoxicity can be effectively attenuated by rutin possessing antioxidant, free-radical scavenger, and anti-lipid per oxidant activities (51). Recently, hepatoprotective mechanisms of rutin in CCl4-intoxicated BALB/cN mice has also been demonstrated (52). Our identification of rutin in *A. javanica* extract by validated HPTLC method further supports its therapeutic use in the prevention and treatment of liver diseases.

Very recently, *A. Javanica*-derived aervecdysteroid A–D (1–4) and acylated flavone glycosides have been shown to inhibit enzymatic activities of lipoxygenase and butyrylcholinesterase (53). In mammals, lipoxygenases catalyze the formation of hydroperoxides as the first step in the biosynthesis of several inflammatory mediators (54). Butyrylcholinesterase, also known as serum or plasma cholinesterase, is synthesized in the liver that hydrolyzes many different choline-based esters. In clinical assays, serum butyrylcholinesterase activity is used as a liver function test for acute and chronic liver damage, including other inflammatory disorder (55). Nevertheless, further biological analysis of these compounds, including identification of other bioactive constituents of *A. javanica*.

Fig. 5. Quantification of rutin in *A. javanica* total ethanolic extract by HPTLC. (a) Pictogram of developed RP-HPTLC plate at 254 nm; mobile phase – acetonitrile: water (4:6, v/v). (b) Chromatogram of standard rutin (1,000 ng spot⁻¹), peak 1 (Rf = 0.65) scanned at 360 nm; mobile phase – acetonitrile: water 4:6, v/v). (c) Chromatogram of the extract containing rutin (peak 6) scanned at 360 nm; mobile phase – acetonitrile: water 4:6, v/v).
with antioxidative and hepatoprotective activities, remains to be explored.

Conclusions
Our investigation of *A. javanica* total ethanol extract revealed its promising antioxidative and hepatoprotective potential against chemically induced liver injury *ex vivo* as well as *in vivo*. This was supported by the *in vitro* phytochemical analysis and identification of rutin, a well-known antioxidant flavonoid. Our finding therefore, suggests the therapeutic potentiality of *A. javanica* in various liver diseases. However, further studies on main active ingredients of the extract, their mechanism of action, and other therapeutic contribution of these interventions would be necessary.

Acknowledgements
This project was funded by the National Plan for Science, Technology and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, Award Number (MED11-1585-02).

Conflicts of interest and funding
The authors declare that they do not have any conflicts of interest.

References
1. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–4.
2. Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol 2014; 20: 14672–85.
3. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 1: S44–8.
4. Aniya Y, Koyama T, Miyagi C, Miyahira M, Inomata C, Murakami T, et al. Hepatoprotective constituents in plants 15: antifungal activities of different crude fractions of *Aerva javanica*. J Pure Appl Microbio 2012; 6: 1849–52.
5. Kumar V, Kaur P, Suttee A. Possible role of alcoholic extract of roots of *Aerva javanica* in cisplatin and gentamicin-induced nephrotoxicity in rats. Indian J Pharmacol 2008; 40: 167.
6. Mufti FUD, Ullah H, Bangash A, Khan N, Hussain S, Ullah F, et al. Antimicrobial activities of *Aerva javanica* and Paeonia emodi plants. Pak J Pharm Sci 2012; 25: 565–9.
7. Khader JA, Ahmad S, AbdElSalam NM, Ullah R, Islam M. Antifungal activities of different crude fractions of *Aerva javanica*. J Pure Appl Microbio 2012; 6: 1849–52.
8. Sharif A, Ahmed E, Malik A, Mukhtar-Ul-Hassan, Munawar MA, Farrukh A, et al. Antimicrobial Constituents from *Aerva javanica*. J Chem Soc Pakistan 2011; 33: 439–43.
9. Mufti FUD, Ullah H, Bangash A, Khan N, Hussain S, Ullah F, et al. Antimicrobial activities of *Aerva javanica* and *Paeonia emodi* plants. Pak J Pharm Sci 2012; 25: 565–9.
10. Al-Said MS, Mothana RA, Al-Yahya MA, Al-Blowi AS, Al-Sohaibani M, Ahmed AF, et al. Edible oils for liver protection: hepatoprotective potentiality of *Moringa oleifera* seed oil against chemical-induced hepatitis in rats. J Food Sci 2012; 77: 124–30.
11. Chawla P, Chawla A, Vasudeva N, Sharma SK. A review of chemistry and biological activities of the genus *Aerva* – a desert plant. Acta Pol Pharm 2012; 69: 171–7.
12. Samejo MQ, Memon S, Bhangar MI, Khan KM. Chemical compositions of the essential oil of *Aerva javanica* leaves and stems. Pak J Anal Environ Chem 2012; 13: 48–51.
13. Khan AW, Jan S, Parveen S, Khan RA, Saeed A, Tanveer AJ, et al. Phytochemical analysis and enzyme inhibition assay of *Aerva javanica* for Uleer. Chem Cent J 2012; 6(1): 76.
14. Ahmed N, Mahmood A, Sadeghi Z, Farman M. Ethnopharmacological importance of medicinal flora from the district of Vehari, Punjab province, Pakistan. J Ethnopharmacol 2015; 168: 66–78.
15. Sharif A, Ahmed E, Malik A, Mukhtar-Ul-Hassan, Munawar MA, Farrukh A, et al. Antimicrobial Constituents from *Aerva javanica*. J Chem Soc Pakistan 2011; 33: 439–43.
16. Mufti FUD, Ullah H, Bangash A, Khan N, Hussain S, Ullah F, et al. Antimicrobial activities of *Aerva javanica* and *Paeonia emodi* plants. Pak J Pharm Sci 2012; 25: 565–9.
17. Khader JA, Ahmad S, AbdElSalam NM, Ullah R, Islam M. Antifungal activities of different crude fractions of *Aerva javanica*. J Pure Appl Microbio 2012; 6: 1849–52.
18. Kumar V, Kaur P, Suttee A. Possible role of alcoholic extract of roots of *Aerva javanica* in cisplatin and gentamicin-induced nephrotoxicity in rats. Indian J Pharmacol 2008; 40: 167.
19. Mussaqid S, Riaz N, Saleemi M, Ashraf M, Ismail T, Jabbab A. New acylated flavonoid glycosides from flowers of *Aerva javanica*. J Asian Nat Prod Res 2013; 15: 708–16.
20. Samejo MQ, Memon S, Bhangar MI, Khan KM. Comparison of chemical composition of *Aerva javanica*seed essential oils obtained by different extraction methods. Pak J Pharm Sci 2013; 26: 757–60.
21. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Arch Pharmacol Res 2011; 34: 767–74.
22. Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric 2012; 92: 1441–7.
23. Li CC, Hsiang CY, Wu SL, Ho TY. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-kappaB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol 2012; 50: 1568–75.
24. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56–63.
25. King EJ, Armstrong AR. Calcium, phosphorus and phosphatase. In: Varley H, ed. Practical clinical biochemistry. New Delhi: CBS, 1988.
26. Fiala S, Fiala AE, Dixon B. Glutamyl transpeptidase in transplantable, chemically induced rat hepatomas and “spontaneous” mouse hepatomas. J Natl Cancer Inst 1972; 48: 1393–401.
27. Stehl A. (Hyperbilirubinemia in liver diseases). Fortschr Med 1982; 100: 842–5.
28. Demacker PN, Hijnmans AG, Vos-Janssen HE, van’t Laar A, Jansen AP. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 1980; 26: 1775–9.
29. Foster LB, Dunn RT. Stable reagents for determination of serum triglycerides by a colorimetric Hantzsch condensation method. Clin Chem 1973; 19: 338–40.
30. Burstein M, Scholnick HR. Turbidimetric estimation of chylo-
microns and very low density lipoproteins in human sera after
precipitation by sodium lauryl sulfate. Biomedicine 1973; 19:
16–19.
31. Utley HG, Bernheim F, Hochstein P. Effect of sulfhydryl
reagents on peroxidation in microsomes. Arch Biochem Biophs
1967; 118: 29–32.
32. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and
nonprotein sulfhydryl groups in tissue with Ellman’s reagent.
Anal Biochem 1968; 25: 192–205.
33. Culling CF. Handbook of histopathological and histochemical
techniques.3rd ed. London: Butterworth; 1974.
34. Lee Y-J, Kim D-B, Lee J, Cho J-H, Kim B, Choi H-S, et al.
35. Miller HE. A simplified method for the evaluation of antiox-
dants. J Am Oil Chem Soc 1971; 48: 91–2.
36. Sarker SD, Latif Z, Gray AI. Natural products isolation. 2nd ed.
Totowa, NJ: Humana Press; 2006.
37. Kar A. Pharmacognosy and pharmacobiotechnology. 2nd ed.
New Delhi: New Age International; 2007.
38. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical
screening and extraction: a review. Int Pharm Sci 2011; 1:
98–106.
39. Rota C, Chignell CF, Mason RP. Evidence for free radical
formation during the oxidation of 2′-7′-dichlorofluorescin to the
fluorescent dye 2′-7′-dichlorofluorescein by horseradish pero-
oxidase: possible implications for oxidative stress measurements.
Free Radic Biol Med 1999; 27: 873–81.
40. Bala A, Haldar PK, Kar B, Naskar S, Mazumder UK. Carbon
tetrachloride: a hepatotoxin causes oxidative stress in murine
peritoneal macrophage and peripheral blood lymphocyte cells.
Immunopharmacol Immunotoxicol 2012; 34: 157–62.
41. Kus I, Ogeturk M, Oner H, Sahin S, Yekeler H, Sarsilmaz M.
Protective effects of melatonin against carbon tetrachloride-
induced hepatotoxicity in rats: a light microscopic and bioche-
chemical study. Cell Biochem Funct 2005; 23: 169–74.
42. Tirkay N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus
bioflavonoid, decreases the oxidative stress produced by carbon
tetrachloride in rat liver and kidney. BMC Pharmacol 2005; 5:
2.
43. Saravanan R, Viswanathan P, Pugaledi KV. Protective effect of
ursolic acid on ethanol-mediated experimental liver damage in
rats. Life Sci 2006; 78: 713–18.
44. Suhail M, Suhail S, Gupta BK, Bharat V. Malondialdehyde
and antioxidant enzymes in maternal and cord blood, and their
correlation in normotensive and preeclamptic women. J Clin Med Res 2009; 1: 150–7.
45. Babu BH, Stylesh BS, Padikkala J. Antioxidant and hepato-
protective effect of Acanthus ilicifolius. Fitoterapia 2001; 72:
272–7.
46. Navarro VJ, Senior JR. Current concepts – drug-related hepato-
toxicity. New Engl J Med 2006; 354: 731–9.
47. Alam MN, Bristi NJ, Rafiquzzaman M. Review on in vivo and
in vitro methods evaluation of antioxidant activity. Saudi Pharm J 2013; 21: 143–52.
48. Kedare SB, Singh RP. Genesis and development of DPPH
method of antioxidant assay. J Food Sci Technol 2011; 48:
412–22.
49. AlAjmi MF, Alam P, Siddiqui NA, Basudan OA, Hussain A.
Quantitative analysis of biomarker rutin in different species of
genus Ficus by validated NP and RP-HPTLC methods. Pak J
Pharm Sci 2015; 28: 2213–20.
50. Hosseinizadeh H, Nassiri-Asl M. Review of the protective effects
of rutin on the metabolic function as an important dietary
flavonoid. J Endocrinol Invest. 2014; 37: 783–8.
51. Janbaz KH, Saeed SA, Gilani AH. Protective effect of rutin
on paracetamol- and CCl4-induced hepatotoxicity in rodents.
Fitoterapia 2002; 73: 557–63.
52. Domitrovic´ R, Jakovac H, Vasiljev Marchesi V, Vladimir-
Knežević S, Cvijanović O, Tadić Z, et al. Differential hepato-
protective mechanisms of rutin and quercetin in CCl4-intoxi-
cated BALB/cN mice. Acta Pharmacol Sin 2012; 33: 1260–70.
53. Prigge ST, Boyington JC, Faig M, Doctor KS, Gaffney
BJ, Amzel LM. Structure and mechanism of lipoxigenases.
Biochimie 1997; 79: 629–36.
54. Saleem M, Musaddiq S, Riaz N, Zubair M, Nasar R,
et al. Ecdysteroids from the flowers of Aerva javanica.
Steroids 2013; 78: 1098–102.
55. Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcho-
linesterase as a prognostic marker: a review of the literature.
J Cachexia Sarcopenia Muscle 2013; 4: 31–9.

*Mohammad K. Parvez
Department of Pharmacognosy
College of Pharmacy
King Saud University
P.O. Box 2457, Riyadh 11451
Saudi Arabia
Email: khalalid_parvez@yahoo.com